Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The B-PRECISE Study
NCT07821177Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of Cisplatin micelle injection (HA132), gemcitabine, fluorouracil and mitomycin c in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Feasibility Failure Rate at 16 weeks. Started Sep 2026; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)gemcitabinefluorouracilmitomycin c
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07821177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07821177.